APOMORPHINE CHALLENGE IN SCHIZOPHRENIA & NORMALS

阿扑吗啡对精神分裂症的挑战

• 批准号: 6305710
• 负责人: MYUNG A LEE
• 金额: $ 0.06万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6305710
• 关键词: adrenocorticotropic hormone; apomorphine; clinical research; clozapine; cortisol; drug interactions; homovanillate; human subject; mental disorder chemotherapy; neuroendocrine system; psychopharmacology; schizophrenia

Plasma adrenocorticotropin hormone and cortisol responses to apmorphine are significantly blunted in patients with schizophrenia (SCH) compared to normal controls. Plasma homovanillic acid levels are positively correlated with basal cortisol levels and inversely correlated with APO-stimulated ACTH and cortisol response in SCH. Chronicc treatment with clozapine and olanzapine enhances the plasma ACTH and cortisol responses to APO and decreases pHVA levels in SCH. The change in the plasma ACTH and cortisol responses to APO or the decrease in pHVA levels, or both, after treatment with clozapine or olanzapine predicts clinical response to clozapine or olanzapine.

与正常对照组相比，精神分裂症（SCH）患者血浆促肾上腺皮质激素和皮质醇对阿扑吗啡的反应明显减弱。 SCH患者血浆高香草酸水平与基础皮质醇水平呈正相关，与APO刺激的ACTH和皮质醇反应呈负相关。慢性氯氮平和奥氮平治疗可增强SCH患者血浆ACTH和皮质醇对APO的反应，降低pHVA水平。在氯氮平或奥氮平治疗后，可预测对氯氮平或奥氮平的临床反应。